Try our Advanced Search for more refined results

Amgen Inc. v. Sanofi

  1. February 23, 2018

    Amgen Denied Full Fed. Circ. Hearing On Repatha Patents

    The full Federal Circuit will not review a panel decision that revived a challenge to Amgen's patents for Repatha, an antibody-based cholesterol treatment, according to a decision issued by the appeals court Friday.

  2. February 07, 2018

    Sanofi Urges Fed. Circ. To Deny Amgen's Redo Bid In IP Row

    Sanofi SA on Tuesday urged the Federal Circuit to stand by its October decision reviving a challenge to Amgen Inc.'s cholesterol medication Repatha, arguing that the panel didn't stray from the court's precedent governing how to test when an antibody is patentable. 

  3. December 07, 2017

    Amgen Urges Full Fed. Circ. Hearing On Repatha Patents

    Drugmaker Amgen asked the Federal Circuit on Wednesday for an en banc rehearing of a decision that revived a challenge to its patents for Repatha, an antibody-based cholesterol treatment, saying a panel abandoned precedent by rejecting a previously used test for patentability of such drugs and finding admissible evidence that post-dates the challenged patents.

  4. October 05, 2017

    Fed. Circ. Erases Amgen Win Over Sanofi Cholesterol Drug

    In a battle involving next-generation cholesterol drugs, the Federal Circuit on Thursday nullified Amgen's patent win over Sanofi and Regeneron Pharmaceuticals, concluding that a district judge wrongly excluded evidence and botched jury instructions.

  5. June 06, 2017

    Amgen Patents Don't Advance Drug Science, Fed. Circ. Told

    Sanofi SA and partner Regeneron Pharmaceuticals urged the Federal Circuit during oral arguments Tuesday to upend a validity finding for Amgen Inc. cholesterol-lowering drug patents, arguing the invention Amgen claims was infringed disclosed no “useful” science.

  6. February 27, 2017

    Eli Lilly, Pfizer Urge Fed. Circ. To Undo Sanofi IP Ruling

    Eli Lilly and Co. and Pfizer Inc. have thrown their support behind Sanofi SA and its partner Regeneron Pharmaceuticals in a Federal Circuit case over patents for a cholesterol-lowering drug, saying in amicus briefs that the appeals court should undo district court decisions that upheld competitor Amgen Inc.'s competing drug patents.

  7. February 08, 2017

    Fed. Circ. Lets Sanofi, Regeneron Sell Drug In Patent Appeal

    Sanofi SA and partner Regeneron Pharmaceuticals can keep selling their cholesterol-lowering drug Praluent while they appeal a jury verdict that upheld Amgen Inc.'s patents for a competing drug therapy, the Federal Circuit ruled Wednesday.

  8. January 25, 2017

    Doctors Urge Fed. Circ. To Keep Cholesterol Drug On Market

    Cardiologists and other medical practitioners filed amicus briefs Tuesday urging the Federal Circuit to stop a permanent injunction issued earlier this month that would pull Sanofi's cholesterol-lowering drug Praluent off the market after a jury found Amgen's patents for a competing product are valid.

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!